Cargando…
CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
Targeted therapies are the state of the art in oncology today, and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials, but few of them really change the therapeutic scenario. Difficulties, either to find antigens that are solely expressed in tu...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579806/ https://www.ncbi.nlm.nih.gov/pubmed/37854601 http://dx.doi.org/10.3389/fimmu.2023.1272681 |